Clinical trialNCT02432560RecruitingObservational

Safety and Durability of Sirolimus for Treatment of LAM

SponsorUniversity of CincinnatiEnrollment600Lymphangioleiomyomatosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Francis X McCormack, MD
University of Cincinnati
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stanford University Medical Center
Stanford, California, United States
Recruiting
National Jewish Health
Denver, Colorado, United States
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Recruiting
Emory University School of Medicine
Atlanta, Georgia, United States
Recruiting
Loyola University Medical Center, Chicago
Maywood, Illinois, United States
Active, not recruiting
Brigham and Women'S Hospital
Boston, Massachusetts, United States
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Recruiting
Mayo Clinic Rochester
Rochester, Minnesota, United States
Active, not recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Recruiting
University of Rochester Medical Center
Rochester, New York, United States
Recruiting
University of Cincinnati
Cincinnati, Ohio, United States
Active, not recruiting
Cleveland Clinic
Cleveland, Ohio, United States
Active, not recruiting
Oregon Health and Science University
Portland, Oregon, United States
Active, not recruiting
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Active, not recruiting
Medical University of South Carolina
Charleston, South Carolina, United States
Active, not recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Active, not recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Active, not recruiting
University of Texas Health Center
Houston, Texas, United States
Active, not recruiting
University of Utah School of Medicine
Salt Lake City, Utah, United States
Active, not recruiting
Swedish Medical Center
Seattle, Washington, United States
Active, not recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Everolimus →Sirolimus →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2015
Primary completion: 31 Jul 2025
Completion: 31 Jul 2025
Last update posted: 24 Dec 2024
Registered enrollment: 600
Registry id: NCT02432560

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.